Page last updated: 2024-12-08

pancuronium

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Pancuronium: A bis-quaternary steroid that is a competitive nicotinic antagonist. As a neuromuscular blocking agent it is more potent than CURARE but has less effect on the circulatory system and on histamine release. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

pancuronium : A steroid ester in which a 5alpha-androstane skeleton is C-3alpha- and C-17beta-disubstituted with acetoxy groups and 2beta- and 16beta-disubstituted with 1-methylpiperidinium-1-yl groups. It is a non-depolarizing curare-mimetic muscle relaxant. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
CuraregenusPlant extracts from several species, including genera STRYCHNOS and Chondodendron, which contain TETRAHYDROISOQUINOLINES that produce PARALYSIS of skeletal muscle. These extracts are toxic and must be used with the administration of artificial respiration.[MeSH]LoganiaceaeA plant family of the order Gentianales, subclass Asteridae, class Magnoliopsida. They have leaflike appendages at the base of the leafstalks, have terminal flower clusters. Petals have four or five overlapping lobes and the fruit is a capsule containing winged or wingless seeds.[MeSH]

Cross-References

ID SourceID
PubMed CID441289
CHEMBL ID185073
CHEBI ID7907
SCHEMBL ID13790650
MeSH IDM0015813

Synonyms (49)

Synonym
chebi:7907 ,
piperidinium, 1,1'-((2beta,3alpha,5alpha,16beta,17beta)-3,17-bis(acetyloxy)androstane-2,16-diyl)bis(1-methyl-)
3alpha,17beta-diacetoxy-2beta,16beta-bis(1-methylpiperidinium-1-yl)-5alpha-androstane
AB00384328-10
AB00384328-09
BPBIO1_001372
PRESTWICK3_001034
BSPBIO_001247
PRESTWICK2_001034
LOPAC0_000887
piperidinium, 1,1'-[(2.beta.,3.alpha.,5.alpha.,16.beta.,17.beta.)-3,17-bis(acetyloxy)androstane-2,16-diyl]bis[1-methyl-, dibromide
[(2s,3s,5s,8r,9s,10s,13s,14s,16s,17r)-17-acetoxy-10,13-dimethyl-2,16-bis(1-methylpiperidin-1-ium-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl] acetate
AB00384328
C07551
pancuronium
DB01337
PRESTWICK0_001034
PRESTWICK1_001034
SPBIO_003098
NCGC00023037-03
NCGC00023037-04
HMS2089M07
NCGC00023037-05
CHEMBL185073
[(2s,3s,5s,8r,9s,10s,13s,14s,16s,17r)-17-acetyloxy-10,13-dimethyl-2,16-bis(1-methylpiperidin-1-ium-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl] acetate
CCG-204969
pancuronium cation
unii-j76uf062fs
j76uf062fs ,
16974-53-1
1-[(1s,2s,4s,5s,7s,10r,11s,13s,14r,15s)-5,14-bis(acetyloxy)-2,15-dimethyl-4-(1-methylpiperidin-1-ium-1-yl)tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-13-yl]-1-methylpiperidin-1-ium
pancuronium [vandf]
1,1'-(3.alpha.,17.beta.-dihydroxy-5.alpha.-androstan-2.beta.,16.beta.-ylene)bis(1-methylpiperidinium) diacetate
pancuronium [who-dd]
vecuronium bromide impurity b [ep impurity]
piperidinium, 1,1'-((2.beta.,3.alpha.,5.alpha.,16.beta.,17.beta.)-3,17-bis(acetyloxy)androstane-2,16-diyl)bis(1-methyl-
gtpl4001
1-[(1s,2s,4s,5s,7s,10r,11s,13s,14r,15s)-5,14-bis(acetyloxy)-2,15-dimethyl-13-(1-methylpiperidin-1-ium-1-yl)tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-4-yl]-1-methylpiperidin-1-ium
DTXSID7048405 ,
SCHEMBL13790650
AB00384328_11
Q424297
NCGC00023037-14
NCGC00023037-09
piperidinium, 1,1'-((2beta,3alpha,5alpha,16beta,17beta)-3,17-bis(acetyloxy)androstane-2,16-diyl)bis(1-methyl)-
dtxcid5028378
1,1'-(3alpha,17beta-dihydroxy-5alpha-androstan-2beta,16beta-ylene)bis(1-methylpiperidinium) diacetate
1,1'-(3,17-bis(acetyloxy)androstane-2,16-diyl)bis(1-methylpiperidinium)
piperidinium, 1,1'-((2beta,3alpha,5alpha,16beta,17beta)-3,17-bis(acetyloxy)androstane-2,16-diyl)bis(1-methyl-

Research Excerpts

Overview

Pancuronium is a neuromuscular blocking agent commonly used to eliminate agitation in sick newborn infants requiring mechanical ventilation. Pancuronium bromide is a nondepolarizing muscle relaxant approved to induce skeletal muscle relaxation during anesthesia.

ExcerptReferenceRelevance
"Pancuronium is a typical non-depolarizing, curare-mimetic, very potent muscle relaxant. "( Patient's death as a result of mistakenly injection of pancuronium.
Kabiesz-Neniczka, S; Korczyńska, M; Kulikowska, J; Nowicka, J; Skowronek, R,
)
1.82
"Pancuronium is a long-duration neuromuscular blocking drug (NMBD) that has been used in anesthetized rabbits at 0.1 mg/kg. "( Comparative pharmacodynamics of pancuronium, cisatracurium, and CW002 in rabbits.
Diaz, LL; Heerdt, PM; Zhang, J, 2014
)
2.13
"Pancuronium is a neuromuscular blocking agent commonly used to eliminate agitation in sick newborn infants requiring mechanical ventilation. "( Pancuronium does not alter the hemodynamic status of piglets after normoxia or hypoxia.
Balaraman, V; Easa, D; Finn, KC; Sim, H; Stevens, EL; Uyehara, CF, 1993
)
3.17
"Pancuronium bromide is a nondepolarizing muscle relaxant approved to induce skeletal muscle relaxation during anesthesia and to facilitate the management of patients undergoing mechanical ventilation. "( Pancuronium bromide.
Feeley, TW; Roizen, MF, 1978
)
3.14
"2. Pancuronium is a reversible inhibitor of both AChE and ChE."( [On the inhibition of cholinesterases by pancuronium (author's transl)].
Schuh, FT, 1977
)
1.04

Effects

Pancuronium has sympathomimetic actions but does not change or lowers systemic blood pressure in some studies of anesthetized humans and dogs. Pancuronium is not suspected of binding to serum proteins.

ExcerptReferenceRelevance
"Pancuronium has sympathomimetic actions but does not change or lowers systemic blood pressure in some studies of anesthetized humans and dogs. "( Comparison of the effects of pancuronium and vecuronium in canine coronary and renal arteries.
Ayajiki, K; Nosaka, S; Okamura, T; Sai, Y; Toda, N, 1998
)
2.03
"Pancuronium has not been suspected of binding to serum proteins. "( Pancuronium binding by serum proteins.
Thompson, JM, 1976
)
3.14

Actions

Pancuronium could inhibit completely CCh-induced contraction at a dose of 30 microM. Pancuronium did not inhibit the specific binding of [(3)H]desipramine to plasma membranes isolated from bovine adrenal medulla.

ExcerptReferenceRelevance
"Pancuronium induced an increase in heart rate (+12%), arterial pressure (+16%) and cardiac index (+8%)."( [Hemodynamic effects of vecuronium in man].
Cousin, MT; Guggiari, M; Lienhart, A; Maneglia, R; Tauvent, A; Viars, P, 1983
)
0.99
"Pancuronium could inhibit completely CCh-induced contraction at a dose of 30 microM, while it could not inhibit completely CCh-induced IP1 accumulation at the same dose."( Steroidal muscle relaxants attenuate the contractile and phosphatidylinositol responses of rat trachea.
Hashimoto, S; Iwanaga, S; Makita, T; Shibata, O; Sumikawa, K; Tsuda, A, 1998
)
1.02
"Pancuronium did not inhibit the specific binding of [(3)H]desipramine to plasma membranes isolated from bovine adrenal medulla."( Inhibition by neuromuscular blocking drugs of norepinephrine transporter in cultured bovine adrenal medullary cells.
Hara, K; Izumi, F; Minami, K; Shigematsu, A; Toyohira, Y; Uryu, K; Yanagihara, N, 2000
)
1.03
"Pancuronium at lower doses increases the response most likely by blocking prejunctional muscarinic receptors (M2) that physiologically inhibit vagally mediated increases in pulmonary resistance."( Actions of enflurane, isoflurane, vecuronium, atracurium, and pancuronium on pulmonary resistance in dogs.
Beck, KC; Brichant, JF; Lindahl, SG; Rehder, K; Vettermann, J, 1988
)
1.24

Treatment

Pancuronium bromide treatment in severely ill, mechanically ventilated infants has been shown to result in lower peak transpulmonary pressure, with an accompanying lower-than-expected incidence of pneumothorax. Pancuronium pretreatment also delayed the recovery of spontaneous ventilation and recovery from neuromuscular block.

ExcerptReferenceRelevance
"Pancuronium pretreatment prolonged the SCh block significantly, whereas other agents shortened the duration of the SCh block."( Five non-depolarizing muscle relaxants in precurarization.
Erkola, O; Kuoppamäki, R; Salmenperä, A, 1983
)
0.99
"Pancuronium bromide treatment in severely ill, mechanically ventilated infants has been shown to result in lower peak transpulmonary pressure, with an accompanying lower-than-expected incidence of pneumothorax. "( Pancuronium and abnormal abdominal roentgenograms.
Crowe, JE; Dillard, RG; Sumner, TE, 1980
)
3.15
"Pancuronium pretreatment also delayed the recovery of spontaneous ventilation and recovery from neuromuscular block (p < 0.05) but this was independent of ethnicity."( Suxamethonium myalgia: an ethnic comparison with and without pancuronium pretreatment.
Aun, CS; Gin, T; Houghton, IT; Lau, JT; Oh, TE, 1993
)
1.25
"The pancuronium pretreated group presented less variable values of serum myoglobin which, when compared to the control group, had a more significant p value (p less than 0.001) than for d-tubocurarine pretreated group (p = 0.003)."( Succinylcholine, fasciculations and myoglobinaemia.
Blanc, VF; Brisson, G; Vaillancourt, G, 1986
)
0.75
"Pretreatment with pancuronium at 6 µg/kg significantly reduced the effect of awakening by nicotine under isoflurane anesthesia (P = 0.044)."( Pancuronium enhances isoflurane anesthesia in rats via inhibition of cerebral nicotinic acetylcholine receptors.
Hobo, S; Miyano, K; Miyazaki, Y; Sunaga, H; Uezono, S, 2016
)
2.2
"Pretreatment with pancuronium produced right and downward shift of ethanol induced contraction."( On mechanism of action of ethanol-induced contraction of frog rectus abdominis.
Kela, AK; Mehta, SC; Mehta, VL; Sharma, AK; Srivastava, AK, 1994
)
0.61
"Pretreatment with pancuronium significantly shortened the time to NMB and prolonged spontaneous recovery from NMB in comparison to the temporal course of NMB after administration of 200 micrograms/kg of mivacurium."( Accelerated onset and delayed recovery of neuromuscular block induced by mivacurium preceded by pancuronium in children.
Brandom, BW; Meretoja, OA; Taivainen, T; Wirtavuori, K, 1993
)
0.83
"Pretreatment with pancuronium abolished fasciculations and produced rapid and excellent muscle relaxation for endotracheal intubation."( Comparative effects of nondepolarizing muscle relaxants on succinycholine-induced fasciculations and postoperative pain.
Akkineni, S; Jadhav, KB; Konchigeri, HN; Patel, KP, 1977
)
0.58
"Pretreatment with pancuronium caused a significantly slower recovery of the TOF ratio (phase II block)."( Pretreatment with pancuronium before suxamethonium administration in patients heterozygous for the usual and the atypical plasma cholinesterase gene.
Hanel, HK; Ostergaard, D; Skovgaard, LT; Viby-Mogensen, J, 1991
)
0.94
"Pretreatment were pancuronium prevented convulsions and hyperthermia, but had no effect on acidemia or changes in cardiovascular parameters after intravenous (i.v.) infusion of phencyclidine (PCP)."( Factors in the lethality of i.v. phencyclidine in conscious dogs.
Davis, WM; Hackett, RB; Obrosky, KW; Waters, IW, 1991
)
0.6
"Treatment with pancuronium was not associated with differences in blood pressure variability."( Investigation of the effects of paralysis by pancuronium on heart rate variability, blood pressure and fluid balance.
Gamsu, HR; Greenall, F; Greenough, A, 1989
)
0.88

Toxicity

ExcerptReferenceRelevance
"A simplified, safe and flexible technique of anesthesia, based on a limited number of relatively cheap drugs, and allowing ventilation with air, was applied to 60 patients undergoing operations of at least 60 minutes' duration."( A simple, cheap, effective and safe procedure for general anesthesia.
Lelkens, JP, 1976
)
0.26
"To compare two oral contraceptive pills, both containing 150 micrograms desogestrel, but with either 20 micrograms (Mercilon) or 30 micrograms (Marvelon/Desolett) ethinyl oestradiol (EE), regarding reliability, cycle control and side effect profile."( Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 micrograms desogestrel and either 30 micrograms or 20 micrograms ethinyl oestradiol.
Akerlund, M; Røde, A; Westergaard, J, 1993
)
0.29

Pharmacokinetics

The pharmacodynamic behaviour upon continuous infusion and bolus administration of pancuronium and vecuronium was studied in cats with and without ligated renal pedicles. For pancuronIUM, there were no statistically significant differences between groups for these pharmacokinetic or pharmacodynamic parameters.

ExcerptReferenceRelevance
"Data about plasma concentration, renal and biliary elimination of tubocurarine, gallamine, alcuronium and pancuronium are taken from the literature for synoptical pharmacokinetic analysis."( Comparative clinical pharmacokinetics of tubocurarine, gallamine, alcuronium and pancuronium.
Agoston, S; Buzello, W, 1978
)
0.7
" The apparent elimination half-life was longer and the total voluem of distribution at steady state larger during halothane anesthesia."( Effect of different anesthetics on the pharmacokinetics and pharmacodynamics of pancuronium in the cat.
Agoston, S; Booij, LH; Crul, JF; Miller, RD; van der Pol, F, 1979
)
0.49
"Plasma concentration curves of patients with normal and impaired renal function are fitted to a tri-exponential function according to an open three compartment pharmacokinetic model."( Pharmacokinetics of pancuronium in patients with normal and impaired renal function.
Agoston, S; Buzello, W, 1978
)
0.58
" The apparent plasma elimination half-life was 46 +/- 7 min (S."( Hypothermia and the pharmacokinetics and pharmacodynamics of pancuronium in the cat.
Agoston, S; Booij, LH; Crul, JF; Ham, J; Miller, RD; van der Pol, F, 1978
)
0.5
" A two-compartment open model was used in the pharmacokinetic analysis of the data."( Pancuronium pharmacokinetics in patients with liver cirrhosis.
Agoston, S; Desmonts, JM; Duvaldestin, P; Henzel, D; Kersten, UW, 1978
)
1.7
" Concurrently, evoked muscle twitch response was monitored for each patient as a measure of the pharmacodynamic effect of the drug."( Clinical pharmacokinetics of pancuronium bromide.
Shanks, CA; Somogyi, AA; Triggs, EJ, 1976
)
0.55
" A tow-compartment open model was used in the pharmacokinetic analysis of the data."( Pharmacokinetics of pancuronium in patients with normal and impaired renal function.
McLeod, K; Rawlins, MD; Watson, MJ, 1976
)
0.58
" In combination with data from subfractionation studies the results indicate that the pharmacokinetic analysis of the hepatic disposition of steroidal muscle relaxants may be used to evaluate actual transport phenomena participating in the hepatic disposition of these drugs."( Pharmacokinetics of steroidal muscle relaxants in isolated perfused rat liver.
Meijer, DK; Mol, WE; Oosting, R; Paanakker, JE; Rombout, F; Scaf, AH, 1992
)
0.28
"To study the effects of succinylcholine on subsequent pharmacodynamics of nondepolarizing muscle relaxants, a comparative pharmacodynamic study was carried out in patients having balanced anesthesia (thiopental, fentanyl, nitrous oxide/oxygen) in whom equipotent doses of pipecuronium (80 micrograms/kg) and pancuronium (100 micrograms/kg) were given with or without prior administration of succinylcholine (1 mg/kg)."( Effects of succinylcholine on the pharmacodynamics of pipecuronium and pancuronium.
Dubois, MY; Fleming, NW; Lea, DE, 1991
)
0.69
" The pharmacokinetic parameters of pipecuronium were compared with those of pancuronium (0."( [Comparative pharmacokinetics of pipecuronium bromide, pancuronium bromide and vecuronium bromide in anesthetized man].
Hanaoka, K; Kushida, Y; Murakami, S; Numata, K; Sugai, N; Yajima, C; Yamamoto, K; Yamamura, H, 1990
)
0.76
" The pharmacokinetic variables in both groups did not differ from those found in an earlier study in healthy normothermic patients."( Pharmacokinetics of pancuronium in patients undergoing coronary artery surgery with and without low dose dopamine.
Agoston, S; Kloppenburg, WD; Proost, JH; Scaf, AH; van der Starre, PJ; Wierda, JM, 1990
)
0.6
" Cumulative dose response curves for vecuronium and the pharmacodynamic variables measured were similar with both anaesthetic agents."( Lack of effects of emulsified propofol ('Diprivan') on vecuronium pharmacodynamics--preliminary results in man.
Booij, LH; Crul, JF; De Grood, PM; Van Beem, HB; Van De Wetering, M; Van Egmond, J, 1985
)
0.27
"The authors used pharmacokinetic and pharmacodynamic modeling to explain the time course of neuromuscular blockade following single or multiple doses of three nondepolarizing muscle relaxants."( A pharmacokinetic explanation for increasing recovery time following larger or repeated doses of nondepolarizing muscle relaxants.
Fisher, DM; Rosen, JI, 1986
)
0.27
" For pancuronium, there were no statistically significant differences between groups for these pharmacokinetic or pharmacodynamic parameters."( Pancuronium and vecuronium pharmacokinetics and pharmacodynamics in younger and elderly adults.
Castagnoli, KP; Fisher, DM; Miller, RD; Rupp, SM, 1987
)
2.23
" Elimination half-life was 6-32 hr (mean +/- SD, 17."( Fentanyl pharmacokinetics and hemodynamic effects in preterm infants during ligation of patent ductus arteriosus.
Collins, C; Crean, P; Klein, J; Koren, G; MacLeod, SM; Roy, WL, 1985
)
0.27
" The pharmacokinetics could be described using a two-compartment open model with a distribution half-life of approximately 4 min and an elimination half-life of approximately 31 min."( Pharmacokinetics and pharmacodynamics of Org NC 45 in man.
Bencini, A; van der Veen, F, 1980
)
0.26
"The neuromuscular blocking characteristics of fazadinium and pancuronium were compared using a general pharmacodynamic model."( Fazadinium and pancuronium: a pharmacodynamic study.
English, MJ; Hull, CJ; Sibbald, A, 1980
)
0.86
" The serum concentration of Org NC 45 was determined by normal-phase high performance liquid chromatography (sensitivity 50 ng ml-1), and a two-compartment open pharmacokinetic model was fitted to resulting data."( Pharmacokinetics of Org NC45 (norcuron) in patients with and without renal failure.
Fahey, MR; Miller, RD; Morris, RB; Nguyen, TL; Upton, RA, 1981
)
0.26
"The pharmacodynamic behaviour upon continuous infusion and bolus administration of pancuronium and vecuronium was studied in cats with and without ligated renal pedicles."( Pharmacodynamics of vecuronium and pancuronium in cats with and without ligated renal pedicles.
Booij, LH; Crul, JF; Van de Pol, F; Vree, TB, 1982
)
0.77
" Data were analyzed by nonlinear regression and fit to a three-compartment pharmacokinetic model and a four-compartment pharmacodynamic model."( Pharmacokinetics and pharmacodynamics of vecuronium (ORG NC45) and pancuronium in anesthetized humans.
Castagnoli, N; Cronnelly, R; Fisher, DM; Gencarelli, P; Miller, RD; Nguyen-Gruenke, L, 1983
)
0.5
"Vecuronium and pancuronium were compared for placental transfer, pharmacokinetic variables, and neonatal effects during cesarean section under general anesthesia."( Pharmacokinetics, placental transfer, and neonatal effects of vecuronium and pancuronium administered during cesarean section.
Abboud, TK; Baysinger, CL; Dailey, PA; Fisher, DM; Kim, KC; Miller, RD; Shinohara, Y; Shnider, SM, 1984
)
0.85
" The pharmacokinetic parameters derived for pancuronium were in the range of previously reported values, except that the mean total systemic plasma clearance (0."( Pharmacokinetic and pharmacodynamic modelling with pancuronium.
Brown, KF; Evans, MA; Shanks, CA; Triggs, EJ, 1984
)
0.78
" Serum data best fit a three-compartment pharmacokinetic model."( Pharmacokinetics and pharmacodynamics of 4-aminopyridine in anesthetized dogs.
Castagnoli, N; Fisher, DM; Miller, RD; Rupp, SM; Shinohara, Y, 1983
)
0.27
" With the use of sophisticated pharmacokinetic and pharmacodynamic models good relationships have been demonstrated between plasma concentrations of the relaxants throughout the entire range of relaxant response."( Clinical pharmacokinetics of the non-depolarising muscle relaxants.
Ramzan, MI; Shanks, CA; Somogyi, AA; Triggs, EJ; Walker, JS,
)
0.13
"This review is an attempt to bring together the pharmacokinetic data on d-tubocurarine and pancuronium with clinical observations on relaxant dosage and effect."( Tubocurarine and pancuronium: a pharmacokinetic view.
Ramzan, MI; Shanks, CA; Somogyi, AA; Triggs, EJ, 1980
)
0.82
"We compared the pharmacodynamic effects and hospital costs of three long-acting neuromuscular blocking drugs in a prospective, randomized, double-blind manner."( Hemodynamic and pharmacodynamic comparison of doxacurium and pipecuronium with pancuronium during induction of cardiac anesthesia: does the benefit justify the cost?
Brooker, RF; Butterworth, JF; Gravlee, GP; Prielipp, RC; Rathmell, JP, 1993
)
0.51
" After administration of a bolus of pancuronium 100 micrograms/kg, an improved fluorimetric assay was used to determine the serum concentrations of pancuronium and the pharmacokinetic variables of pancuronium were calculated with a 3P87 program."( Effects of enflurane and isoflurane anesthesia on the pharmacokinetics of pancuronium in adult patients.
Luo, L; Sun, B; Xue, F; Zou, Q, 1996
)
0.8
"An approach based on disposition decomposition analysis (DDA) and the hysteresis minimization principle has been developed for pharmacodynamic modeling."( Disposition decomposition analysis for pharmacodynamic modeling of the link compartment.
Cheng, H; Jusko, WJ, 1996
)
0.29
"In this paper, we investigate the ability of fuzzy to adapt the parameters of a pharmacokinetic and pharmacodynamic model-based controller for the delivery of the muscle relaxant pancuronium."( Fuzzy logic for model adaptation of a pharmacokinetic-based closed loop delivery system for pancuronium.
Johnson, JO; Kern, SE; Westenskow, DR, 1997
)
0.71
" In the current study we performed a pharmacokinetic analysis by measuring the plasma concentration of mivacurium when preceded by administration of a low dose of pancuronium."( Potentiation of mivacurium blockade by low dose of pancuronium: a pharmacokinetic study.
Bouleau, D; Combes, X; Duvaldestin, P; Farinotti, R; Feiss, P; Kirov, K; Menad, R; Motamed, C, 2003
)
0.77
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35

Compound-Compound Interactions

The neuromuscular effects of enflurane in combination with dTc or pancuronium are not significantly different from those seen suring equi-MAC isoflurane anesthesia. Compared to vecuronium, pancuronIUM increased heart rate, and protected from arterial hypotension, when combined with low-dose alfentanil.

ExcerptReferenceRelevance
" Also, neuromuscular effects of enflurane in combination with dTc or pancuronium are not significantly different from those seen suring equi-MAC isoflurane anesthesia."( Neuromuscular effects of enflurane, alone and combined with d-Tubocurarine, pancuronium, and succinylcholine, in man.
Fogdall, RP; Miller, RD, 1975
)
0.72
" Compared to vecuronium, pancuronium increased heart rate, and protected from arterial hypotension, when combined with low-dose alfentanil."( Alfentanil combined with vecuronium or pancuronium: haemodynamic implications.
Oikkonen, M, 1992
)
0.86
"The usefulness of alfentanil for eye surgery, when combined with either vecuronium or pancuronium, was evaluated in 44 fit anticholinergized patients."( Alfentanil combined with vecuronium or pancuronium for use in eye surgery.
Oikkonen, MP, 1992
)
0.78
"The effect of trimetaphan alone and in combination with pancuronium, tubocurarine or metocurine (dimethyl tubocurarine) has been examined on the rat phrenic nerve diaphragm preparation."( The neuromuscular blocking effect of trimetaphan alone and in combination with different non-depolarizing muscle relaxants in the rat.
Pollard, BJ; van der Spek, AF, 1987
)
0.52
" Therefore the application of etomidate as a continuous infusion in combination with fentanyl and nitrous oxide 66% seems to be an effective technique of intravenous anaesthesia."( [The influence on the cardiovascular system of etomidate infusion anaesthesia combined with fentanyl/nitrous oxide (author's transl)].
Hoffmann, P; Schockenhoff, B, 1981
)
0.26

Dosage Studied

Cumulative dose-response curves of suxamethonium, tubocurarine, and pancuronium were constructed in 142 patients under enflurane and halothane anesthesia, and neuroleptic anesthesia.

ExcerptRelevanceReference
"This experiment was carried out upon the male-adulte-AF SPF-Wister Rat, anesthetized by the use of pentobarbital-Na at the only dosage of 40 mg/kg/IP and put under artificial ventilation."( [Variations in the activity of various curarizing substances as a function of the time of administration].
Agopian, B; Bouyard, P; Bruguerolle, B; Jadot, G; Mesdjian, E; Valli, M, 1975
)
0.25
" The average dosage of 4 mg did not effect the maternal blood pressure, fetal muscle tonus and cardiorespiratory adaption of the newborn."( [The effects of Pavulon (pancuronium bromide) on maternal circulation and metabolism as well as on fetal metabolism and postnatal condition at Caesarean section (author's transl)].
Dauss, I; Klausch, B; Plesse, R; Stark, KH, 1979
)
0.56
" Each of the three groups of children who were treated with one of the three curare-like agents were subdivided according to age and dose-response curves were obtained."( [Comparative study of the neuromuscular effects of 3 curare-like agents in children].
Goudsouzian, NG; Mathieu, A; Nishan, G, 1979
)
0.26
"Intravenous dose-response relationships were used to correlate neuromuscular paralysis with effects on autonomic mechanisms in anaesthetized cats."( Effects on non-depolarizing neuromuscular blocking agents on peripheral autonomic mechanisms in cats.
Chapple, DJ; Hughes, R, 1976
)
0.26
" The times from start of recovery to return of twitch tension to 25, 50, and 75 per cent of control were similar in the different dosage groups, but occurred progressively later with increasing doses."( Relationship of the serum concentration of pancuronium to its neuromuscular activity in man.
Agoston, S; Crul, JF; Kersten, UW; Scaf, AH, 1977
)
0.52
" This supersensitivity was manifest as a parallel leftward shift of the dose-response curve for noradrenaline with no alteration of the maximum response to the agonist."( On the mechanism of pancuronium-induced supersensitivity to noradrenaline in rat smooth muscle.
Tomlinson, DR, 1979
)
0.58
" To avoid excessive dosage during prolonged surgery for total biliary obstruction, it is recommended that supramaximal nerve stimulation be used to indicate the need for the administration of further doses of pancuronium."( Disposition kinetics of pancuronium bromide in patients with total biliary obstruction.
Shanks, CA; Somogyi, AA; Triggs, EJ, 1977
)
0.75
"To determine the potency of pancuronium and its metabolites, 3-OH-, 17-OH- and 3,17-OH-pancuronium, cumulative dose-response curves were determined in five anesthetized patients with each drug."( The comparative potency and pharmacokinetics of pancuronium and its metabolites in anesthetized man.
Agoston, S; Booij, LH; Crul, JF; Ham, J; Kersten, UW; Miller, RD, 1978
)
0.81
" Pancuronium produced no change in isometric contraction of rabbit atrial or cat papillary muscle but displaced the acetylcholine dose-response curve to the right in the papillary muscle preparations, verifying a muscarinic blocking effect of this drug."( The myocardial effects of pancuronium.
Duke, PC; Fung, H; Gartner, J, 1975
)
1.46
" A programmed level of muscle paralysis is therefore possible for use in physiological and pharmacological experiments, and in clinical practice where precise control of the degree of paralysis together with minimal dosage is advantageous."( Computer controlled muscle relaxation: a comparison of four muscle relaxants in the sheep.
Brown, WA; Cass, NM; Coles, JR; Lampard, DG, 1976
)
0.26
"Cumulative dose-response curves were constructed from evoked compound electromyographic (EMG) recordings in man to compare the sensitivity to pancuronium of the adductor pollicis, the hypothenar and the first dorsal interosseous muscles."( Differential effect of pancuronium at the adductor pollicis, the first dorsal interosseous and the hypothenar muscles. An electromyographic and mechanomyographic dose-response study.
Engbaek, J; Roed, J, 1992
)
0.8
" The dosage of pancuronium was 100 micrograms/kg given as required to inhibit spontaneous respiration."( Effect of morphine and pancuronium on the stress response in ventilated preterm infants.
Dean, HG; Levene, MI; Otoo, F; Puntis, JW; Quinn, MW; Rushforth, JA; Wild, J, 1992
)
0.95
" From cumulative dose-response curves the ED50 and ED90 were calculated to be 175 and 300 micrograms/kg, respectively."( Dose-response relation, neuromuscular blocking action, intubation conditions, and cardiovascular effects of Org 9273, a new neuromuscular blocking agent.
Lambalk, LM; Richardson, FJ; van den Broek, L; Wierda, JM, 1991
)
0.28
" In addition, the block/fade relationships for cumulative dosing and sequential dilution were the same when measurements were made at steady-state for several doses."( Relationships between block-of-twitch and train-of-four fade in the mouse phrenic nerve-diaphragm preparation.
Rosenberg, H; Slomowitz, SA; Storella, RJ, 1991
)
0.28
" Clinical information includes diagnoses, dosage of neuromuscular junction blocker, other medications affecting the neuromuscular system, and neuromuscular examination and clinical course."( Prolonged paralysis after treatment with neuromuscular junction blocking agents.
Balbierz, JM; Clemmer, TP; Gooch, JL; Petajan, JH; Suchyta, MR, 1991
)
0.28
" All studied drugs proved to be safe at the administered dosage with regard to their influence on cerebral hemodynamics in very immature infants."( Cerebral hemodynamics in perinatal pharmacology.
Jorch, G; Rabe, H, 1991
)
0.28
" Before its introduction into clinical practice in the USA, in the first phase of this study the neuromuscular potency of pipecuronium was determined under "balanced" and enflurance anaesthesia by the cumulative log dose-response method in 30 patients each."( Neuromuscular and cardiovascular effects of pipecuronium.
Duncalf, D; Foldes, FF; Goldiner, PL; Nagashima, H; Nguyen, HD, 1990
)
0.28
" Other 191 patients were divided into three groups according to the type and dosage of pretreatment as follows: VB 20 micrograms."( [Influence of small doses of vecuronium and pancuronium on succinylcholine-induced neuromuscular blockade].
Nishizawa, M, 1990
)
0.54
" Also, the dose-response relationships of pancuronium and succinylcholine in surgical patients during anesthesia with desflurane (n = 13) were compared to those during isoflurane anesthesia (n = 14)."( The neuromuscular effects of desflurane, alone and combined with pancuronium or succinylcholine in humans.
Caldwell, JE; Eger, EI; Heier, T; Laster, MJ; Lynam, DP; Magorian, T; Weiskopf, RB; Yasuda, N, 1991
)
0.78
" Cumulative dose-response curves were determined for pancuronium, and ED50 was calculated from each of the 5 curves."( [The effect of RO15-1788 on the interaction between pancuronium and diazepam].
Amaki, Y; Hajiri, H; Kaneko, M; Kobayashi, K; Kumagai, M; Shudo, Y, 1990
)
0.78
" Dose-response curves of pancuronium were parallel in all age-groups."( Dose-response characteristics of pancuronium in neonates, infants and children.
Luosto, T; Meretoja, OA, 1990
)
0.86
"The dose-response to pancuronium was determined in identical twins within an hour with the same anesthetic technique."( Dose-response to pancuronium in identical twins.
Goudsouzian, N, 1990
)
0.94
" Cases where the dosage of MDP would be influenced by neurological, hemodynamic, or painful diagnoses were excluded."( Age-related differences in the use of morphine, diazepam, and pancuronium for mechanically ventilated children.
Albert, MA; Lucking, SE; Mickell, JJ; Pedigo, SA, 1990
)
0.52
" The dose-response values obtained were fitted to a regression embedded in a split plot factorial experimental design such as both to control and to measure effects of variation among preparations, order of administration, time, and level of block."( Interaction among agents that block end-plate depolarization competitively.
Waud, BE; Waud, DR, 1985
)
0.27
" The relative cutaneous histamine-releasing ability of each drug was derived from calculated dose-response relationships."( Comparative cutaneous histamine release by neuromuscular blocking agents.
Galletly, DC, 1986
)
0.27
"Cumulative dose-response curves were constructed to determine the comparative potency of pipecuronium and pancuronium."( Comparative potency of pipecuronium bromide and pancuronium bromide.
Mirakhur, RK; Stanley, JC, 1989
)
0.75
" Prior administration of succinylcholine was associated with a leftward shift of dose-response curve of vecuronium or pancuronium."( [The effect of succinylcholine on vecuronium and pancuronium].
Kosaka, F; Manabe, N; Morita, K; Ohta, Y; Ono, K, 1989
)
0.74
" We conclude that there is no clinical indication that the dosage of atracurium and vecuronium during inhalation anesthesia should be reduced, but the doses of pipecuronium and pancuronium should be reduced when prolonged paralysis is not desired."( Interaction between nondepolarizing neuromuscular blocking agents and inhalational anesthetics.
Agoston, S; Hermans, J; Ket, JM; Koot, HW; Rashkovsky, OM; Swen, J, 1989
)
0.47
"The dose-response relationship and the doses of atropine required to prevent neostigmine from lowering heart rates below baseline in 50 per cent (ED50) and 95 percent (ED95) of patients after antagonism of pancuronium-induced neuromuscular blockade were determined in 70 patients with neostigmine-atropine mixtures."( Atropine-neostigmine mixture: a dose-response study.
Gomaa, M; Naguib, M, 1989
)
0.46
" A dose-response relationship for the effect on the arterial capacitance could not be demonstrated."( Effect of N2O on segmental left ventricular function and effective arterial elastance in pigs when added to a halothane-fentanyl-pancuronium anesthetic technique.
Badenhorst, E; Bolliger, C; Coetzee, A; Fourie, P; Lombard, C; Rebel, A, 1989
)
0.48
"The purpose of this study was to compare the incremental, cumulative dose method and the single bolus injection technique for construction of dose-response curves for vecuronium."( Dose-response curves for vecuronium during halothane and neurolept anaesthesia: single bolus versus cumulative method.
Engbaek, J; Ording, H; Skovgaard, LT; Viby-Mogensen, J, 1985
)
0.27
"To evaluate possible potentiation of neuromuscular blocking effect of a combination of vecuronium and d-tubocurarine, cumulative dose-response curves were constructed to compare the potency of this combination with vecuronium and d-tubocurarine given alone."( Vecuronium and d-tubocurarine combination: potentiation of effect.
Ferres, CJ; Gibson, FM; Mirakhur, RK, 1985
)
0.27
" With reduced dosage and with careful neuromuscular monitoring, vecuronium can be used safely in the myasthenic patient."( Vecuronium in the myasthenic patient.
Bell, CF; Florence, AM; Hunter, JM; Jones, RS; Utting, JE, 1985
)
0.27
" The sizes of the bolus injections were based on previously determined cumulative dose-response relationships."( Neuromuscular blocking effects of atracurium, vecuronium and pancuronium during bolus and infusion administration.
Gramstad, L; Lilleaasen, P, 1985
)
0.51
" Although the time to maximum NMB following divided doses of pancuronium, atracurium or vecuronium is significantly longer than that for succinylcholine, divided dosing significantly decreases the time required to reach maximal NMB."( Accelerated onset of non-depolarizing neuromuscular blocking drugs: pancuronium, atracurium and vecuronium. A comparison with succinylcholine.
Gergis, SD; Mehta, MP; Sokoll, MD, 1988
)
0.75
" These simulations allow the user to contrast the time-course of relaxation to be expected with various dosage regimens."( Simulating the time-course of clinical paralysis.
Shanks, CA, 1988
)
0.27
" When the drug was administered in divided dosage the onset time was reduced, the block was more intense and its duration of action was prolonged."( Accelerated onset of pancuronium with divided doses.
Bevan, DR; Breen, PJ; Doherty, WG; Donati, F, 1985
)
0.59
" This situation demonstrates the difficulties of assessing the level of sedation as well as the dosage requirements in this type of patient."( Detection of overdosage of sedation in a patient with renal failure by the absence of lower oesophageal motility.
Sinclair, ME; Suter, PM, 1988
)
0.27
"The dose-response and the doses required to prevent bradycardia in 50% (ED50) and 95% (ED95) of patients were determined for atropine after antagonism of pancuronium-induced neuromuscular blockade in 72 patients with edrophonium-atropine mixtures."( Atropine-edrophonium mixture: a dose-response study.
Absood, GH; Gomaa, M; Naguib, M, 1988
)
0.47
"To determine the potencies of neostigmine, pyridostigmine, and edrophonium in reversing pancuronium and d-tubocurarine blockade, dose-response curves were established for first twitch height recovery and train-of-four ratio."( Dose-response curves for edrophonium, neostigmine, and pyridostigmine after pancuronium and d-tubocurarine.
Antzaka, C; Bevan, DR; Donati, F; McCarroll, SM; McCready, D, 1987
)
0.72
" The dose-response curves for pancuronium were similar using the two methods, and resulted in an ED95 (dose required to produce 95% block of the twitch height) of 60 and 59 micrograms kg-1 using single-dose and cumulative-dose methods respectively."( Dose-response curves for pancuronium and tubocurarine: comparison of single and cumulative dose techniques.
Gibson, FM; Mirakhur, RK, 1987
)
0.86
" Concentrations of anticholinesterases spanned the clinical range and were extended beyond to establish dose-response curves."( Incomplete reversal of pancuronium neuromuscular blockade by neostigmine, pyridostigmine, and edrophonium.
Bartkowski, RR, 1987
)
0.58
" Dose-response relationships were established from the measurement of first twitch height (T1) ten minutes later."( Neostigmine, pyridostigmine and edrophonium as antagonists of deep pancuronium blockade.
Bevan, DR; Donati, F; Lahoud, J; McCready, D, 1987
)
0.51
" Pancuronium cumulative dose-response curves for both muscles were determined in 10 ASA Class I adults."( Potency of pancuronium at the diaphragm and the adductor pollicis muscle in humans.
Antzaka, C; Bevan, DR; Donati, F, 1986
)
1.57
" The dosage rate is automatically adjusted at 10-second intervals, according to the measured evoked, rectified, integrated electromyogram."( Clinical automatic control of neuromuscular blockade.
Asbury, AJ; Linkens, DA, 1986
)
0.27
" Secondly, cats chronically were treated with 2 mg X kg-1 of intramuscular hydrocortisone three times a week for 1 month, and then dose-response curves were constructed for pancuronium or succinylcholine."( The effects of acute and chronic hydrocortisone treatment on neuromuscular blockade in the anesthetized cat.
Briscoe, JR; Durant, NN; Katz, RL, 1984
)
0.46
" Cumulative dose responses studied in six cats showed that the NC 45 dosage required to produce 85--95% tibialis block was slightly greater than controls during respiratory and metabolic alkalosis."( Effects of changes in acid-base balance on neuromuscular blockade produced by ORG-NC 45.
Crul, JF; Funk, DI; Pol, FM, 1980
)
0.26
" No evidence supporting the concept that dosage should be related to patient's weight was found."( Reduction of post-suxamethonium pain by pretreatment with four non-depolarizing agents.
Bennetts, FE; Khalil, KI, 1981
)
0.26
" The dose-response relationships for the antagonism of Org NC 45 and pancuronium neuromuscular blockades were not significantly different."( Antagonism of org NC 45 (vecuronium) and pancuronium neuromuscular blockade by neostigmine.
Gencarelli, PJ; Miller, RD, 1982
)
0.76
"The potencies of atracurium, Org NC 45 and pancuronium were determined using cumulative dose-response curves."( Dose-response relation for atracurium, ORG NC 45 and pancuronium.
Gramstad, L; Lilleaasen, P, 1982
)
0.78
"To compare two methods of estimating the potency of neuromuscular relaxants of medium duration, the authors determined the potency of vecuronium (ORG NC45) using cumulative dose-response (CDR) techniques, and compared these data with published values from our group obtained using the single bolus technique."( Potency determination for vecuronium (ORG NC45): comparison of cumulative and single-dose techniques.
Cronnelly, R; Fahey, MR; Fisher, DM; Miller, RD, 1982
)
0.26
" They then compared these dose-response relationships with values obtained for adults (greater than 18 years old) under comparable anesthetic conditions."( Neuromuscular effects of vecuronium (ORG NC45) in infants and children during N2O, halothane anesthesia.
Fisher, DM; Miller, RD, 1983
)
0.27
" and an infusion (150 micrograms kg-1 min-1 for 30 min and 75 micrograms kg-1 min-1 thereafter) on the pharmacodynamics and dose-response curves of atracurium and vecuronium were studied in 52 healthy (ASA I or II) patients."( Some effects of diisopropyl phenol (ICI 35 868) on the pharmacodynamics of atracurium and vecuronium in anaesthetized man.
Booij, LH; Crul, JF; Fragen, RJ; Robertson, EN; van Egmond, J, 1983
)
0.27
" Ten adolescents and ten children were given 20 micrograms/kg incremental doses of vecuronium to establish a cumulative dose-response curve during train-of-four stimulation."( Safety and efficacy of vecuronium in adolescents and children.
Gionfriddo, M; Goudsouzian, NG; Liu, LM; Martyn, JJ, 1983
)
0.27
"The dose-response curves of vecuronium and pancuronium were compared during ketamine anaesthesia in 60 patients (ASA I)."( Dose-response relationships and neuromuscular blocking effects of vecuronium pancuronium during ketamine anaesthesia.
Engbaek, J; Ording, H; Pedersen, T; Viby-Mogensen, J, 1984
)
0.76
" Atracurium also does not depend on hepatic function for metabolism; however, vecuronium may require dosing adjustments in hepatic disease."( Atracurium and vecuronium: two unique neuromuscular blocking agents.
Conner, CS, 1984
)
0.27
" The dose-response curves for the three groups did not differ from each other and no potentiation was demonstrated."( Dose-response studies with pancuronium, vecuronium and their combination.
Clarke, RS; Ferres, CJ; Gibson, FM; Mirakhur, RK; Pandit, SK, 1984
)
0.56
" For each drug at each temperature, a dose-response curve for twitch depression was constructed."( Pancuronium, unlike other nondepolarizing relaxants, retains potency at hypothermia.
Bartkowski, RR; Horrow, JC, 1983
)
1.71
"Pancuronium bromide was administered to calves to define the dosage level necessary to produce surgical relaxation (90% to 99% reduction of base-line evoked, hindlimb digital-extensor muscle twitch tension)."( Neuromuscular and cardiovascular effects of pancuronium bromide in calves anesthetized with halothane.
Hildebrand, SV; Howitt, GA, 1984
)
1.97
" Dosage levels were determined by giving small increments (0."( Dosage requirement of pancuronium in halothane-anesthetized ponies: a comparison of cumulative and single-dose administration.
Hildebrand, SV; Howitt, GA, 1984
)
0.58
"Cumulative dose-response curves of suxamethonium, tubocurarine, and pancuronium were constructed in 142 patients under enflurane and halothane anesthesia, and neuroleptic anesthesia (control group)."( Differential increase in potency of neuromuscular blocking agents by enflurane and halothane.
Schuh, FT, 1983
)
0.5
"Cumulative dose-response curves were constructed for pancuronium, metocurine, d-tubocurarine and gallamine in 56 children anaesthetized with thiopentone, N2O/O2 and narcotic."( The dose response effect of long-acting nondepolarizing neuromuscular blocking agents in children.
Ali, HH; Goudsouzian, NG; Liu, LM; Martyn, JJ, 1984
)
0.52
" Dose-response curves for pancuronium, duration of blockade, and adequacy of relaxation for tracheal intubation did not differ between patients receiving midazolam (N = 10) or thiopental (N = 10)."( Comparison of thiopental and midazolam on the neuromuscular responses to succinylcholine or pancuronium in humans.
Cronnelly, R; Miller, RD; Morris, RB, 1983
)
0.79
" Dosage regimens have been designed using knowledge of the disposition kinetics of the relaxants to provide for continuous adequate relaxation during prolonged surgical procedures."( Clinical pharmacokinetics of the non-depolarising muscle relaxants.
Ramzan, MI; Shanks, CA; Somogyi, AA; Triggs, EJ; Walker, JS,
)
0.13
"Cumulative dose-response curves were constructed in man for tubocurarine, pancuronium, gallamine and alcuronium from data obtained during barbiturate-narcotic-nitrous oxide anaesthesia."( Dose-response curves for four neuromuscular blockers using continuous i.v. infusion.
Ramzan, MI; Shanks, CA; Triggs, EJ; Walker, JS, 1981
)
0.49
" The dosage pattern consisted of a loading phase before any IEMG depression was detected, an onset phase during which a moderate amount of drug was required to achieve increasing paralysis, and a maintenance phase during which a substantially constant and relatively low infusion rate was required."( Dosage patterns of non-depolarizing neuromuscular blockers in the sheep.
Brown, WA; Cass, N; Lampard, DG; Ng, KC, 1980
)
0.26
"This review is an attempt to bring together the pharmacokinetic data on d-tubocurarine and pancuronium with clinical observations on relaxant dosage and effect."( Tubocurarine and pancuronium: a pharmacokinetic view.
Ramzan, MI; Shanks, CA; Somogyi, AA; Triggs, EJ, 1980
)
0.82
" Over the physiological range of concentrations of potassium and calcium, 36% and 27% variation in dosage can be expected."( Interaction of calcium and potassium with neuromuscular blocking agents.
Waud, BE; Waud, DR, 1980
)
0.26
"The potencies of suxamethonium, pancuronium, and tubocurarine were increased, as shown by a parallel shift to the left of cumulative dose-response curves, following normovolaemic haemodilution before operation."( Influence off haemodilution on the potency of neuromuscular blocking drugs.
Schuh, FT, 1981
)
0.55
" Subsequently he had an adequate response with a standard dosage of pancuronium."( Atracurium resistance in a critically Ill patient.
Hoey, LL; Nahum, A; Tschida, SJ; Vance-Bryan, K,
)
0.37
" Firstly we established dose-response curves for mivacurium and pancuronium."( Synergism between mivacurium and pancuronium in adults.
Erkola, O; Meretoja, OA; Rautoma, P, 1995
)
0.81
" We undertook an open label study to evaluate the efficacy and dosing requirements for a less costly drug, pancuronium."( Pancuronium infusion for neuromuscular block in children in the pediatric intensive care unit.
Garrett, JS; Lynch, A; McDuffee, A; Tobias, JD, 1995
)
1.95
" We studied the dose-response relationships of each drug and their combination with rocuronium in 200 ASA I or II patients during propofol-fentanyl-nitrous oxide-oxygen anaesthesia."( Comparative potency of steroidal neuromuscular blocking drugs and isobolographic analysis of the interaction between rocuronium and other aminosteroids.
Bakhamees, HS; el-Bakry, AK; Magboul, MA; Naguib, M; Samarkandi, AH, 1995
)
0.29
"4 mg/kg) and maintained with fentanyl (total dosage 70-100 micrograms/kg)."( [Anesthesia for heart transplantation in newborn and suckling infants. Special aspects of the hypoplastic left heart syndrome].
Bauer, J; Boldt, J; Dapper, F; Hempelmann, G; Knothe, C; Zickmann, B, 1995
)
0.29
"This study was designed to evaluate the dose-response effects of different doses of clonidine on the stress response to laryngoscopy and endotracheal intubation."( Dose-response effects of intravenous clonidine on stress response during induction of anesthesia in coronary artery bypass graft patients.
Kulka, PJ; Tryba, M; Zenz, M, 1995
)
0.29
" These guidelines recommend clinical indications for these agents and dosing ranges reflecting current medical opinion."( The role of nondepolarizing neuromuscular blocking agents in mechanically ventilated patients.
May, JR; Rutkowski, AF, 1994
)
0.29
" We found that atracurium was prescribed for 68% of study patients; 68% of the patients did not have renal, hepatic, or cardiovascular disease; dosages of NNMBAs varied; a statistically significant increase in dosage requirements over time occurred with atracurium; assessment of neuromuscular blockade was 100% subjective; and 41% and 17% of patients receiving atracurium and vecuronium, respectively, experienced prolonged neuromuscular weakness documented subjectively."( A retrospective analysis of long-term use of nondepolarizing neuromuscular blocking agents in the intensive care unit, and guidelines for drug selection.
Clarens, DM; Gilliland, SS; Kelly, KJ; Kohls, PK; Nahum, A; Vance-Bryan, K,
)
0.13
" The dose-response curve (DRC) constructed from log-probit transformation for the group not receiving nitrous oxide shifted to the right for 10."( [Potentiation of pancuronium induced neuromuscular blockade by nitrous oxide].
Tsuchiya, A, 1994
)
0.63
" For groups 2 and 6, atracurium was administered at a dosage of 4 mg/kg of body weight, followed by a continuous infusion of 15 mg/kg/h."( Porphyrinogenic effects of atracurium, vecuronium, and pancuronium in a primed rat model.
Bach, A; Böhrer, H; Bolsen, K; Goerz, G; Kohl, B; Martin, E; Schmidt, H, 1994
)
0.54
" We and others have previously shown that substitution of phenylalanine for tyrosine at position 198 of the alpha subunit (alpha Y198F) leads to a rightward shift in the dose-response curve for acetylcholine-elicited currents."( Selective enhancement of the interaction of curare with the nicotinic acetylcholine receptor.
Aylwin, ML; Filatov, GN; White, MM, 1993
)
0.29
"To describe a previously unreported event in which a patient became refractory to atracurium-induced neuromuscular blockade, but subsequently was adequately paralyzed with a standard dosage of pancuronium."( Response to pancuronium after loss of atracurium-induced neuromuscular blockade.
Clarens, DM; Kelly, KJ; Kohls, PR; Nahum, A; Vance-Bryan, K,
)
0.7
"We have compared the dose-response relationships of mivacurium, pancuronium and their combination, and examined the interactions by isobolographic and fractional analyses."( Interactions between mivacurium and pancuronium.
Kim, DW; Kim, S; Shim, JC, 1997
)
0.81
"To evaluate the dose-response and maintenance requirements of a combination of mivacurium and pancuronium (cMP) in clinical practice."( Potency and hourly maintenance requirement of combinations of mivacurium and pancuronium in adults.
Erkola, O; Meretoja, OA; Rautoma, P, 1998
)
0.75
" Thirty patients received mivacurium and 20 patients received pancuronium to establish dose-response curves for these agents."( Potency and hourly maintenance requirement of combinations of mivacurium and pancuronium in adults.
Erkola, O; Meretoja, OA; Rautoma, P, 1998
)
0.77
"Seventy-eight subjects were randomly assigned to receive one of four dosing combinations for intubation and neuromuscular maintenance: rocuronium for intubation and maintenance, rocuronium for intubation and pancuronium for maintenance, pancuronium for intubation and rocuronium for maintenance, or pancuronium for both."( Impact of the initial doses of rocuronium and pancuronium on subsequent maintenance for neuromuscular block.
Fitzgerald, PC; Fragen, RJ; Johnson, JO; Kern, SE; van Zeeland, M, 2001
)
0.76
" Anesthetic management and muscle relaxant maintenance dosing were standardized."( Impact of shorter-acting neuromuscular blocking agents on fast-track recovery of the cardiac surgical patient.
Avram, MJ; Marymont, JH; Murphy, GS; Rosengart, TK; Szokol, JW; Vender, JS, 2002
)
0.31
" Drug combinations containing equipotent concentrations of two agents were tested and dose-response curves were determined."( Isobolographic analysis of non-depolarising muscle relaxant interactions at their receptor site.
Dipp, NC; Fokt, RM; Kindler, CH; Paul, M; Yost, CS, 2002
)
0.31
"To compare dosing requirements over time among patients receiving continuous cisatracurium versus pancuronium therapy, and to identify factors that may account for changes in pancuronium versus cisatracurium infusion requirements over time."( Tachyphylaxis associated with continuous cisatracurium versus pancuronium therapy.
Barletta, JF; Devlin, JW; Janisse, JJ; Kanji, S; Kruse, JA, 2002
)
0.77
" Factors that could affect dosing requirements of a neuromuscular blocking agent (NMBA) were stratified as time invariant (admitting service, acute physiology and chronic health evaluation II score, duration of mechanical ventilation, pressure control ventilation, baseline hepatic or renal insufficiency, thermal injury, train-of-four assessment, and concurrent drug administration or disorders affecting neuromuscular transmission) or time variant (concurrent sedation and narcotic analgesia therapy; serum magnesium, potassium, and creatinine concentrations; arterial pH level; temperature; peak airway pressure; and partial pressure of oxygen:fraction of inspired oxygen ratio)."( Tachyphylaxis associated with continuous cisatracurium versus pancuronium therapy.
Barletta, JF; Devlin, JW; Janisse, JJ; Kanji, S; Kruse, JA, 2002
)
0.56
" Plasma cholinesterase activity was measured before and 3 and 30 min after pancuronium dosing in the pancuronium-mivacurium group and was measured before and after administration of saline in the mivacurium group."( Potentiation of mivacurium blockade by low dose of pancuronium: a pharmacokinetic study.
Bouleau, D; Combes, X; Duvaldestin, P; Farinotti, R; Feiss, P; Kirov, K; Menad, R; Motamed, C, 2003
)
0.8
" However, critical hemoglobin was significantly higher in the animals receiving the higher anesthetic dosage (1."( Tolerance to acute isovolemic hemodilution. Effect of anesthetic depth.
De Hert, S; Degroote, F; Mathieu, N; Schmartz, D; Van der Linden, P; Vincent, JL; Zhang, H, 2003
)
0.32
" Dosage or duration of aminoglycosides use did not relate to SNHL."( Ototoxic drugs and sensorineural hearing loss following severe neonatal respiratory failure.
Cheung, PY; Etches, PC; Peliowski, A; Robertson, CM; Tyebkhan, JM, 2006
)
0.33
" Thus, it is not recommended to increase the lidocaine dosage during ECC."( Compartmental analysis of lidocaine kinetics during extracorporeal circulation.
Feo, L; Mezza, A; Monaco, C; Schiavello, R; Sciarra, M, 1988
)
0.27
" Execution outcomes from North Carolina and California together with interspecies dosage scaling of thiopental effects suggest that in the current practice of lethal injection, thiopental might not be fatal and might be insufficient to induce surgical anesthesia for the duration of the execution."( Lethal injection for execution: chemical asphyxiation?
Koniaris, LG; López-Muñoz, F; Lubarsky, DA; Sheldon, J; Waterman, L; Weisman, R; Zimmers, TA, 2007
)
0.34
"Low-dose pancuronium is known to affect serum cholinesterase activity (BChE); however, the dose-response effect of clinical doses of pancuronium on BChE has not been investigated."( Dose-response effect of serum butyrylcholinesterase activity after clinical doses of pancuronium.
Duvaldestin, P; Fanen, P; Feiss, P; Kirov, K; Motamed, C, 2008
)
0.99
" Most of the debate has surrounded the dosing and procedures used in lethal injection and whether the drug combinations and measures for administering the drugs truly produce a timely, pain-free, and fail-safe death."( Issues surrounding lethal injection as a means of capital punishment.
Fink, JL; Romanelli, F; Whisman, T, 2008
)
0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
muscle relaxantA drug used to produce muscle relaxation (excepting neuromuscular blocking agents). Its primary clinical and therapeutic use is the treatment of muscle spasm and immobility associated with strains, sprains, and injuries of the back and, to a lesser degree, injuries to the neck. Also used for the treatment of a variety of clinical conditions that have in common only the presence of skeletal muscle hyperactivity, for example, the muscle spasms that can occur in multiple sclerosis.
cholinergic antagonistAny drug that binds to but does not activate cholinergic receptors, thereby blocking the actions of acetylcholine or cholinergic agonists.
nicotinic antagonistAn antagonist at the nicotinic cholinergic receptor.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
steroid ester
acetate esterAny carboxylic ester where the carboxylic acid component is acetic acid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
thioredoxin reductaseRattus norvegicus (Norway rat)Potency0.00530.100020.879379.4328AID588453
GLS proteinHomo sapiens (human)Potency35.48130.35487.935539.8107AID624146
arylsulfatase AHomo sapiens (human)Potency0.06751.069113.955137.9330AID720538
serine/threonine-protein kinase mTOR isoform 1Homo sapiens (human)Potency0.20750.00378.618923.2809AID2660
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (58)

Assay IDTitleYearJournalArticle
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID386623Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1412202Inhibition of Neisseria meningitidis LgtC at 50 uM using UDP-Gal donor substrate incubated for 20 mins by malachite green reagent based colorimetric method relative to control2018MedChemComm, Jan-01, Volume: 9, Issue:1
Identification of non-substrate-like glycosyltransferase inhibitors from library screening: pitfalls & hits.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID219380Inhibition of superior cervical nerve-induced contractions of the nictitating membrane in anesthetized cats2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Non-depolarizing neuromuscular blocking activity of bisquaternary amino di- and tripeptide derivatives.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID218977-logED50 value for chick biventer determined.2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Non-depolarizing neuromuscular blocking activity of bisquaternary amino di- and tripeptide derivatives.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID218864Dose causing 50% block of muscle twitch in isolated chick biventer cervicis muscle (Decrease in baseline tension)2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Non-depolarizing neuromuscular blocking activity of bisquaternary amino di- and tripeptide derivatives.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1412203Inhibition of Neisseria meningitidis LgtC using UDP-Gal donor substrate incubated for 20 mins by malachite green reagent based colorimetric method2018MedChemComm, Jan-01, Volume: 9, Issue:1
Identification of non-substrate-like glycosyltransferase inhibitors from library screening: pitfalls & hits.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID219389Duration (90%) measured for NMB activity in anesthetized cats2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Non-depolarizing neuromuscular blocking activity of bisquaternary amino di- and tripeptide derivatives.
AID241212Inhibition of apamin-sensitive SKCa channel of guinea-pig hepatocytes2004Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15
Defining determinant molecular properties for the blockade of the apamin-sensitive SKCa channel in guinea-pig hepatocytes: the influence of polarizability and molecular geometry.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID219390Onset time was measured for NMB activity in anesthetized cats2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Non-depolarizing neuromuscular blocking activity of bisquaternary amino di- and tripeptide derivatives.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID219383Inhibitory potency in anesthetized cats, and Onset time is reported2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Non-depolarizing neuromuscular blocking activity of bisquaternary amino di- and tripeptide derivatives.
AID681573TP_TRANSPORTER: uptake (electrogenesis) in Xenopus laevis oocytes1996The Journal of biological chemistry, Dec-20, Volume: 271, Issue:51
Electrogenic properties and substrate specificity of the polyspecific rat cation transporter rOCT1.
AID219192pre and post-block increases in twitch tension an short lived muscle fasiculations 20-30s after dosing determined; ND is No Data.2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Non-depolarizing neuromuscular blocking activity of bisquaternary amino di- and tripeptide derivatives.
AID1412205Effect on inorganic phosphate reaction with malachite green reagent at 1 mM after 20 mins by colorimetric method2018MedChemComm, Jan-01, Volume: 9, Issue:1
Identification of non-substrate-like glycosyltransferase inhibitors from library screening: pitfalls & hits.
AID219391Recovery time (25-75 %) measured for NMB activity in anesthetized cats2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Non-depolarizing neuromuscular blocking activity of bisquaternary amino di- and tripeptide derivatives.
AID219378Inhibition of stimulated vagus nerve-induced bradycardia in anesthetized cats2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Non-depolarizing neuromuscular blocking activity of bisquaternary amino di- and tripeptide derivatives.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID21877Calculated partition coefficient (clogP)2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Non-depolarizing neuromuscular blocking activity of bisquaternary amino di- and tripeptide derivatives.
AID1412204Inhibition of calf intestinal phosphatase up to 100 uM using UDP as substrate measured after 20 mins by malachite green reagent based colorimetric method2018MedChemComm, Jan-01, Volume: 9, Issue:1
Identification of non-substrate-like glycosyltransferase inhibitors from library screening: pitfalls & hits.
AID681953TP_TRANSPORTER: inhibition of MPP+ uptake (MPP+: 0.85 uM, Pancuronium: 1000 uM) in Xenopus laevis oocytes1997Molecular pharmacology, Jun, Volume: 51, Issue:6
Cloning and functional expression of a human liver organic cation transporter.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,018)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901402 (69.47)18.7374
1990's417 (20.66)18.2507
2000's145 (7.19)29.6817
2010's45 (2.23)24.3611
2020's9 (0.45)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 61.28

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index61.28 (24.57)
Research Supply Index7.84 (2.92)
Research Growth Index4.04 (4.65)
Search Engine Demand Index107.96 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (61.28)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials345 (15.77%)5.53%
Reviews65 (2.97%)6.00%
Case Studies283 (12.93%)4.05%
Observational1 (0.05%)0.25%
Other1,494 (68.28%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]